Trial Profile

A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Letrozole (Primary) ; Sirolimus (Primary)
Indications Carcinoma; Endometrial cancer
Focus Therapeutic Use
Sponsors Aadi Bioscience

Most Recent Events

07 Aug 2024 According to an Aadi media release, initial data from this trial expected by the end of the year.
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
23 May 2024 According to an Aadi Bioscience media release, company will present a trials-in-progress poster on Phase 2 trial in advanced or recurrent endometrioid-type endometrial cancer (EEC).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com